# SGLT2 Inhibitors in Glomerular Hyperfiltration

> **NCT04143581** · PHASE2 · WITHDRAWN · sponsor: **Mario Negri Institute for Pharmacological Research**

## Conditions studied

- Obesity
- Non-diabetic Chronic Kidney Disease

## Interventions

- **DRUG:** Empagliflozin 10 MG

## Key facts

- **NCT ID:** NCT04143581
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-09-03
- **Primary completion:** 2021-09-03
- **Final completion:** 2021-09-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funds
- **Last updated:** 2021-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04143581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04143581, "SGLT2 Inhibitors in Glomerular Hyperfiltration". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04143581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*